Allogene Therapeutics, Inc. (ALLO)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 30M 60M 90M Q2 '21: 44K Q3 '21: 49K Q4 '21: 75.7M Q1 '22: 61K Q2 '22: 86K Q3 '22: 49K Q4 '22: 26K Q1 '23: 30K Q2 '23: 22K Q3 '23: 22K Q4 '23: 21K Q1 '24: 22K Q2 '24: 0 Q3 '24: 0 Q4 '24: 0 Q1 '25: 0 Q2 '25: 0 Q3 '25: 0 Q4 '25: 0 Q2 '26: 4.6M Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25 Q2 '26

Gross Profit Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Quarterly

-105M -70M -35M 0 35M 70M 105M Q3 '21: -77.7M Q4 '21: 1.7M Q1 '22: -80M Q2 '22: -76.6M Q3 '22: -82.5M Q4 '22: -96.4M Q1 '23: -99.1M Q2 '23: -80.5M Q3 '23: -63M Q4 '23: -85.1M Q1 '24: -69.5M Q2 '24: -71.4M Q3 '24: -71.8M Q4 '24: -60.5M Q1 '25: -65.2M Q2 '25: -56.8M Q3 '25: -44.9M Q4 '25: -42.4M Q1 '26: -46.1M Q2 '26: -46.9M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-105M -70M -35M 0 35M 70M 105M Q3 '21: -78.2M Q4 '21: 86K Q1 '22: -79.8M Q2 '22: -74.8M Q3 '22: -83.1M Q4 '22: -97.3M Q1 '23: -100M Q2 '23: -79.2M Q3 '23: -62.3M Q4 '23: -85.8M Q1 '24: -65M Q2 '24: -66.4M Q3 '24: -66.3M Q4 '24: -59.9M Q1 '25: -59.7M Q2 '25: -50.9M Q3 '25: -41.4M Q4 '25: -38.8M Q1 '26: -42.6M Q2 '26: -42.7M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Quarterly

-75M -50M -25M 0 25M 50M 75M Q3 '21: -48.9M Q4 '21: -45.4M Q1 '22: -68.2M Q2 '22: -42.5M Q3 '22: -47.7M Q4 '22: -62.1M Q1 '23: -66.6M Q2 '23: -61.9M Q3 '23: -55.5M Q4 '23: -53.7M Q1 '24: -55.9M Q2 '24: -63.6M Q3 '24: -44.1M Q4 '24: -36.7M Q1 '25: -52.9M Q2 '25: -39M Q3 '25: -29.7M Q4 '25: -27.6M Q1 '26: -12.9M Q2 '26: -32M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-75M -50M -25M 0 25M 50M 75M Q3 '21: -52.2M Q4 '21: -46.2M Q1 '22: -70.1M Q2 '22: -43.9M Q3 '22: -47.9M Q4 '22: -63.8M Q1 '23: -67.7M Q2 '23: -62.1M Q3 '23: -55.5M Q4 '23: -53.9M Q1 '24: -55.9M Q2 '24: -63.6M Q3 '24: -44.5M Q4 '24: -37M Q1 '25: -53M Q2 '25: -39.1M Q3 '25: -29.9M Q4 '25: -27.6M Q1 '26: -12.9M Q2 '26: -32.1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 150M 300M 450M Q2 '20: 115.4M Q3 '20: 127.1M Q1 '21: 132.2M Q2 '21: 134.8M Q3 '21: 137M Q1 '22: 141.4M Q2 '22: 143.4M Q3 '22: 143.7M Q1 '23: 144.6M Q2 '23: 146.8M Q3 '23: 167.6M Q1 '24: 169.1M Q2 '24: 190M Q3 '24: 209.2M Q1 '25: 215.4M Q2 '25: 218.9M Q3 '25: 222M Q1 '26: 240.3M Q2 '26: 328.9M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-2.70 -1.80 -0.90 0.00 0.90 1.80 2.70 Q3 '21: -2.43 Q4 '21: -1.34 Q1 '22: -1.65 Q2 '22: -1.64 Q3 '22: -1.65 Q4 '22: -2.34 Q1 '23: -2.47 Q2 '23: -2.49 Q3 '23: -2.28 Q4 '23: -2.11 Q1 '24: -1.80 Q2 '24: -1.61 Q3 '24: -1.56 Q4 '24: -1.33 Q1 '25: -1.23 Q2 '25: -1.11 Q3 '25: -0.98 Q4 '25: -0.87 Q1 '26: -0.77 Q2 '26: -0.67 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.